Levetiracetam Liderfarm

Levetiracetam, the active ingredient in Levetiracetam Liderfarm, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients with epilepsy, and is prescribed by neurologists worldwide. The drug is formulated to provide consistent plasma concentrations and is absorbed rapidly after ingestion.

GNH USA supplies Levetiracetam Liderfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures timely delivery to qualified healthcare providers.

Levetiracetam is an antiepileptic drug used to control various seizure types.

- Partial seizures: reduces the frequency and severity of focal onset seizures, improving daily functioning. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in generalized epilepsy, decreasing seizure burden. - Myoclonic seizures: decreases myoclonic jerks in patients with juvenile myoclonic epilepsy, enhancing safety and quality of life.

Levetiracetam may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Nausea: feeling of queasiness, sometimes accompanied by vomiting. - Somnolence: increased daytime sleepiness. - Irritability: heightened emotional responsiveness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood changes: depression, anxiety, or suicidal thoughts. - Hematologic abnormalities: low blood counts such as neutropenia or thrombocytopenia.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

- Renal function: adjust dose in patients with impaired clearance. - Psychiatric history: monitor for mood alterations or suicidal ideation. - Concomitant CNS depressants: assess additive sedation risk. - Pregnancy: evaluate benefit‑risk ratio; limited data available. - Elderly patients: start at lower dose and titrate cautiously. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Phenytoin: may modestly decrease levetiracetam exposure; monitor seizure frequency. - Valproic acid: potential for increased adverse effects; observe for CNS depression. - Oral contraceptives: levetiracetam may slightly reduce hormonal efficacy; advise additional contraceptive measures.